• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (5100842)   Today's Articles (4455)
For: Charlton M. Telaprevir, boceprevir, cytochrome P450 and immunosuppressive agents--a potentially lethal cocktail. Hepatology 2011;54:3-5. [PMID: 21710471 DOI: 10.1002/hep.24470] [Citation(s) in RCA: 66] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Number Cited by Other Article(s)
1
McCain JD, Chascsa DM. Special Considerations in the Management of HIV and Viral Hepatitis Coinfections in Liver Transplantation. Hepat Med 2022;14:27-36. [PMID: 35514530 PMCID: PMC9063796 DOI: 10.2147/hmer.s282662] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/11/2021] [Accepted: 04/07/2022] [Indexed: 11/26/2022]  Open
2
Eisenberger U, Friebus-Kardash J, Guberina H, Kribben A, Witzke O, Willuweit K, Gerken G, Herzer K. Treatment With Grazoprevir/Elbasvir for Renal Transplant Recipients With Chronic Hepatitis C Virus Infection and Impaired Allograft Function. Transplant Direct 2019;5:e419. [PMID: 30656217 PMCID: PMC6324915 DOI: 10.1097/txd.0000000000000860] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2018] [Revised: 09/26/2018] [Accepted: 11/14/2018] [Indexed: 02/07/2023]  Open
3
Huang F, Voelk C, Trampisch M, Rowland L, Schultz A, Sabo JP. Pharmacokinetic Interaction between Faldaprevir and Cyclosporine or Tacrolimus in Healthy Volunteers: A Prospective, Open-Label, Fixed-Sequence, Crossover Study. Basic Clin Pharmacol Toxicol 2018;123:84-93. [PMID: 29427400 DOI: 10.1111/bcpt.12980] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2017] [Accepted: 01/31/2018] [Indexed: 12/14/2022]
4
Herzer K, Welzel TM, Spengler U, Hinrichsen H, Klinker H, Berg T, Ferenci P, Peck-Radosavljevic M, Inderson A, Zhao Y, Jimenez-Exposito MJ, Zeuzem S. Real-world experience with daclatasvir plus sofosbuvir ± ribavirin for post-liver transplant HCV recurrence and severe liver disease. Transpl Int 2017;30:243-255. [PMID: 28012215 DOI: 10.1111/tri.12910] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2016] [Revised: 11/18/2016] [Accepted: 12/13/2016] [Indexed: 02/06/2023]
5
Habib S, Malik S, Fu B, Chang J, Nalesnik M, Humar A, Shaikh OS. Hepatitis C in Liver Allograft Recipients: Utility of One-Year Post-Transplantation Biopsy as an Indicator of Antiviral Therapy. Gastroenterology Res 2016;8:281-290. [PMID: 27785310 PMCID: PMC5051027 DOI: 10.14740/gr694w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 12/15/2015] [Indexed: 12/02/2022]  Open
6
Shinoda M, Ebinuma H, Itano O, Yamagishi Y, Obara H, Kitago M, Nakamoto N, Hibi T, Yagi H, Abe Y, Matsubara K, Chu PS, Wakayama Y, Taniki N, Yamaguchi A, Amemiya R, Miyake R, Mizota T, Kanai T, Kitagawa Y. Simeprevir/pegylated interferon/ribavirin triple therapy for recurrent hepatitis C after living donor liver transplantation. Hepatol Res 2016;46:1118-1128. [PMID: 26854748 DOI: 10.1111/hepr.12666] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/29/2015] [Revised: 01/31/2016] [Accepted: 01/31/2016] [Indexed: 12/13/2022]
7
Hull M, Shafran S, Wong A, Tseng A, Giguère P, Barrett L, Haider S, Conway B, Klein M, Cooper C. CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core Research Group: 2016 Updated Canadian HIV/Hepatitis C Adult Guidelines for Management and Treatment. THE CANADIAN JOURNAL OF INFECTIOUS DISEASES & MEDICAL MICROBIOLOGY = JOURNAL CANADIEN DES MALADIES INFECTIEUSES ET DE LA MICROBIOLOGIE MEDICALE 2016;2016:4385643. [PMID: 27471521 PMCID: PMC4947683 DOI: 10.1155/2016/4385643] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 09/25/2015] [Accepted: 12/15/2015] [Indexed: 12/13/2022]
8
Chung CY, Liu CH, Burnouf T, Wang GH, Chang SP, Jassey A, Tai CJ, Tai CJ, Huang CJ, Richardson CD, Yen MH, Lin CC, Lin LT. Activity-based and fraction-guided analysis of Phyllanthus urinaria identifies loliolide as a potent inhibitor of hepatitis C virus entry. Antiviral Res 2016;130:58-68. [PMID: 27012176 DOI: 10.1016/j.antiviral.2016.03.012] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2015] [Revised: 03/16/2016] [Accepted: 03/19/2016] [Indexed: 12/22/2022]
9
Herzer K, Papadopoulos-Köhn A, Walker A, Achterfeld A, Paul A, Canbay A, Timm J, Gerken G. Daclatasvir, Simeprevir and Ribavirin as a Promising Interferon-Free Triple Regimen for HCV Recurrence after Liver Transplant. Digestion 2016;91:326-33. [PMID: 25999053 DOI: 10.1159/000382075] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/17/2015] [Accepted: 03/31/2015] [Indexed: 02/04/2023]
10
Daily low-dose tacrolimus is a safe and effective immunosuppressive regimen during telaprevir-based triple therapy for hepatitis C virus recurrence after liver transplant. Transplantation 2015;99:841-7. [PMID: 25208324 DOI: 10.1097/tp.0000000000000399] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
11
Herzer K, Papadopoulos-Köhn A, Achterfeld A, Canbay A, Piras-Straub K, Paul A, Walker A, Timm J, Gerken G. Management of telaprevir-based triple therapy for hepatitis C virus recurrence post liver transplant. World J Hepatol 2015;7:1287-1296. [PMID: 26019745 PMCID: PMC4438504 DOI: 10.4254/wjh.v7.i9.1287] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/15/2014] [Revised: 02/27/2015] [Accepted: 04/02/2015] [Indexed: 02/06/2023]  Open
12
Zimner-Rapuch S, Janus N, Deray G, Launay-Vacher V. New therapies for hepatitis C: considerations in patients with renal impairment. Drugs 2015;74:1307-13. [PMID: 25060981 DOI: 10.1007/s40265-014-0268-7] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
13
Eley T, Sevinsky H, Huang SP, He B, Zhu K, Kandoussi H, Gardiner D, Grasela DM, Bertz R, Bifano M. The pharmacokinetics of daclatasvir and asunaprevir administered in combination in studies in healthy subjects and patients infected with hepatitis C virus. Clin Drug Investig 2015;34:661-71. [PMID: 25117173 DOI: 10.1007/s40261-014-0219-9] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
14
Herzer K, Gerken G. Hepatitis C virus reinfection after liver transplant: New chances and new challenges in the era of direct-acting antiviral agents. World J Hepatol 2015;7:532-538. [PMID: 25848476 PMCID: PMC4381175 DOI: 10.4254/wjh.v7.i3.532] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/29/2014] [Revised: 10/21/2014] [Accepted: 12/17/2014] [Indexed: 02/06/2023]  Open
15
Webster DP, Klenerman P, Dusheiko GM. Hepatitis C. Lancet 2015;385:1124-35. [PMID: 25687730 PMCID: PMC4878852 DOI: 10.1016/s0140-6736(14)62401-6] [Citation(s) in RCA: 349] [Impact Index Per Article: 34.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
16
Xiao F, Fofana I, Thumann C, Mailly L, Alles R, Robinet E, Meyer N, Schaeffer M, Habersetzer F, Doffoël M, Leyssen P, Neyts J, Zeisel MB, Baumert TF. Synergy of entry inhibitors with direct-acting antivirals uncovers novel combinations for prevention and treatment of hepatitis C. Gut 2015;64:483-94. [PMID: 24848265 PMCID: PMC4345833 DOI: 10.1136/gutjnl-2013-306155] [Citation(s) in RCA: 75] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
17
Lemaitre F, Jezequel C, Verdier MC, Dermu M, Boglione-Kerrien C, Boudjema K, Bellissant E. Lack of drug interaction between cyclosporine and telaprevir in a liver transplant recipient. Transpl Infect Dis 2015;17:106-10. [PMID: 25573697 DOI: 10.1111/tid.12335] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2014] [Revised: 09/05/2014] [Accepted: 10/07/2014] [Indexed: 11/27/2022]
18
Kwo PY, Mantry PS, Coakley E, Te HS, Vargas HE, Brown R, Gordon F, Levitsky J, Terrault NA, Burton JR, Xie W, Setze C, Badri P, Pilot-Matias T, Vilchez RA, Forns X. An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med 2014;371:2375-82. [PMID: 25386767 DOI: 10.1056/nejmoa1408921] [Citation(s) in RCA: 314] [Impact Index Per Article: 28.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
19
Recurrent HCV after liver transplantation-mechanisms, assessment and therapy. Nat Rev Gastroenterol Hepatol 2014;11:710-21. [PMID: 25023032 DOI: 10.1038/nrgastro.2014.114] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
20
Vercauteren K, Mesalam AA, Leroux-Roels G, Meuleman P. Impact of lipids and lipoproteins on hepatitis C virus infection and virus neutralization. World J Gastroenterol 2014;20:15975-91. [PMID: 25473151 PMCID: PMC4239485 DOI: 10.3748/wjg.v20.i43.15975] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/28/2014] [Revised: 07/09/2014] [Accepted: 09/05/2014] [Indexed: 02/06/2023]  Open
21
Prevention of hepatitis C virus infection by adoptive allogeneic immunotherapy using suicide gene-modified lymphocytes: an in vitro proof-of-concept. Gene Ther 2014;22:172-80. [PMID: 25394253 DOI: 10.1038/gt.2014.99] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2014] [Revised: 08/06/2014] [Accepted: 09/30/2014] [Indexed: 11/08/2022]
22
Kawaoka T, Takahashi S, Tatsukawa Y, Hiramatsu A, Hiraga N, Miki D, Tsuge M, Imamura M, Kawakami Y, Aikata H, Ochi H, Ishiyama K, Ide K, Tashiro H, Ohdan H, Chayama K. Two patients treated with pegylated interferon/ribavirin/telaprevir triple therapy for recurrent hepatitis C after living donor liver transplantation. Hepatol Res 2014;44:1259-64. [PMID: 24382214 DOI: 10.1111/hepr.12296] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/03/2013] [Revised: 11/11/2013] [Accepted: 12/26/2013] [Indexed: 12/13/2022]
23
Vercauteren K, Van Den Eede N, Mesalam AA, Belouzard S, Catanese MT, Bankwitz D, Wong-Staal F, Cortese R, Dubuisson J, Rice CM, Pietschmann T, Leroux-Roels G, Nicosia A, Meuleman P. Successful anti-scavenger receptor class B type I (SR-BI) monoclonal antibody therapy in humanized mice after challenge with HCV variants with in vitro resistance to SR-BI-targeting agents. Hepatology 2014;60:1508-18. [PMID: 24797654 PMCID: PMC4211977 DOI: 10.1002/hep.27196] [Citation(s) in RCA: 51] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/19/2014] [Accepted: 04/29/2014] [Indexed: 02/06/2023]
24
Delaborde L, Logerot S, Fonrose X. [Drug-drug interaction with telaprevir or boceprevir in liver transplant patients: about four cases]. Therapie 2014;69:491-7. [PMID: 25320939 DOI: 10.2515/therapie/2014201] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2014] [Accepted: 07/28/2014] [Indexed: 01/12/2023]
25
Miller MH, Agarwal K, Austin A, Brown A, Barclay ST, Dundas P, Dusheiko GM, Foster GR, Fox R, Hayes PC, Leen C, Millson C, Ryder SD, Tait J, Ustianowski A, Dillon JF. Review article: 2014 UK consensus guidelines - hepatitis C management and direct-acting anti-viral therapy. Aliment Pharmacol Ther 2014;39:1363-75. [PMID: 24754233 DOI: 10.1111/apt.12764] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/11/2014] [Revised: 03/03/2014] [Accepted: 04/01/2014] [Indexed: 12/12/2022]
26
Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience. J Hepatol 2014;60:78-86. [PMID: 23994384 DOI: 10.1016/j.jhep.2013.08.018] [Citation(s) in RCA: 146] [Impact Index Per Article: 13.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/18/2013] [Revised: 07/16/2013] [Accepted: 08/15/2013] [Indexed: 02/06/2023]
27
Satapathy SK, Fiel MI, Vanatta JM, Del Rio Martin J, Schiano TD. Recurrent hepatitis C virus infection and outcome after living-donor liver transplant. EXP CLIN TRANSPLANT 2013;11:522-529. [PMID: 23901801 DOI: 10.6002/ect.2013.0054] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
28
Bush CO, Pokrovskii MV, Saito R, Morganelli P, Canales E, Clarke MO, Lazerwith SE, Golde J, Reid BG, Babaoglu K, Pagratis N, Zhong W, Delaney WE, Paulson MS, Beran RKF. A small-molecule inhibitor of hepatitis C virus infectivity. Antimicrob Agents Chemother 2013;58:386-96. [PMID: 24165192 PMCID: PMC3910743 DOI: 10.1128/aac.02083-13] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2013] [Accepted: 10/24/2013] [Indexed: 02/06/2023]  Open
29
Lupberger J, Duong FHT, Fofana I, Zona L, Xiao F, Thumann C, Durand SC, Pessaux P, Zeisel MB, Heim MH, Baumert TF. Epidermal growth factor receptor signaling impairs the antiviral activity of interferon-alpha. Hepatology 2013;58:1225-35. [PMID: 23519785 DOI: 10.1002/hep.26404] [Citation(s) in RCA: 55] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/17/2012] [Revised: 02/28/2013] [Accepted: 03/12/2013] [Indexed: 02/06/2023]
30
Berenguer Berenguer J, González-García J. [Pharmacokinetic interactions of telaprevir with other drugs]. Enferm Infecc Microbiol Clin 2013;31 Suppl 3:37-48. [PMID: 24063902 DOI: 10.1016/s0213-005x(13)70123-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
31
Conteduca V, Sansonno D, Russi S, Pavone F, Dammacco F. Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents. J Infect 2013;68:1-20. [PMID: 24012819 DOI: 10.1016/j.jinf.2013.08.019] [Citation(s) in RCA: 53] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2013] [Revised: 08/07/2013] [Accepted: 08/22/2013] [Indexed: 02/06/2023]
32
Pungpapong S, Aqel BA, Koning L, Murphy JL, Henry TM, Ryland KL, Yataco ML, Satyanarayana R, Rosser BG, Vargas HE, Charlton MR, Keaveny AP. Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation. Liver Transpl 2013;19:690-700. [PMID: 23696372 DOI: 10.1002/lt.23669] [Citation(s) in RCA: 90] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/01/2012] [Accepted: 03/31/2013] [Indexed: 02/06/2023]
33
Crespo G, Carrión JA, Coto-Llerena M, Mariño Z, Lens S, Pérez-Del-Pulgar S, García-Retortillo M, Miquel R, Bosch J, Navasa M, Forns X. Combinations of simple baseline variables accurately predict sustained virological response in patients with recurrent hepatitis C after liver transplantation. J Gastroenterol 2013;48:762-9. [PMID: 23011083 DOI: 10.1007/s00535-012-0680-2] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/11/2012] [Accepted: 08/29/2012] [Indexed: 02/04/2023]
34
Fofana I, Xiao F, Thumann C, Turek M, Zona L, Tawar RG, Grunert F, Thompson J, Zeisel MB, Baumert TF. A novel monoclonal anti-CD81 antibody produced by genetic immunization efficiently inhibits Hepatitis C virus cell-cell transmission. PLoS One 2013;8:e64221. [PMID: 23704981 PMCID: PMC3660333 DOI: 10.1371/journal.pone.0064221] [Citation(s) in RCA: 48] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2013] [Accepted: 04/12/2013] [Indexed: 12/15/2022]  Open
35
Biggins SW, Trotter J, Gralla J, Burton JR, Bambha KM, Dodge J, Brocato M, Cheng L, McQueen M, Forman L, Chang M, Kam I, Everson G, Spritz RA, Klintmalm G, Rosen HR. Differential effects of donor and recipient IL28B and DDX58 SNPs on severity of HCV after liver transplantation. J Hepatol 2013;58:969-76. [PMID: 23333445 PMCID: PMC3878646 DOI: 10.1016/j.jhep.2012.12.027] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/06/2012] [Revised: 12/01/2012] [Accepted: 12/27/2012] [Indexed: 12/15/2022]
36
Friman S. Recurrence of Disease After Liver Transplantation. Transplant Proc 2013;45:1178-81. [DOI: 10.1016/j.transproceed.2012.10.009] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
37
Burger D, Back D, Buggisch P, Buti M, Craxí A, Foster G, Klinker H, Larrey D, Nikitin I, Pol S, Puoti M, Romero-Gómez M, Wedemeyer H, Zeuzem S. Clinical management of drug-drug interactions in HCV therapy: challenges and solutions. J Hepatol 2013;58:792-800. [PMID: 23137766 DOI: 10.1016/j.jhep.2012.10.027] [Citation(s) in RCA: 93] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/17/2012] [Revised: 10/22/2012] [Accepted: 10/25/2012] [Indexed: 12/16/2022]
38
Chávez-Tapia NC, Ridruejo E, Alves de Mattos A, Bessone F, Daruich J, Sánchez-Ávila JF, Cheinquer H, Zapata R, Uribe M, Bosques-Padilla F, Gadano A, Sosa A, Dávalos-Moscol M, Marroni C, Muñoz-Espinoza L, Castro-Narro G, Paraná R, Méndez-Sánchez N. An update on the management of hepatitis C: guidelines for protease inhibitor-based triple therapy from the Latin American Association for the Study of the Liver. Ann Hepatol 2013;12 Suppl 2:s3-s35. [PMID: 23559487 DOI: 10.1016/s1665-2681(19)31404-8] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2025]
39
Safety and anti-HCV effect of prolonged intravenous silibinin in HCV genotype 1 subjects in the immediate liver transplant period. J Hepatol 2013;58:421-6. [PMID: 23073223 DOI: 10.1016/j.jhep.2012.10.009] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/01/2012] [Revised: 10/01/2012] [Accepted: 10/08/2012] [Indexed: 01/16/2023]
40
Hull M, Klein M, Shafran S, Tseng A, Giguère P, Côté P, Poliquin M, Cooper C. CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core: Canadian guidelines for management and treatment of HIV/hepatitis C coinfection in adults. THE CANADIAN JOURNAL OF INFECTIOUS DISEASES & MEDICAL MICROBIOLOGY = JOURNAL CANADIEN DES MALADIES INFECTIEUSES ET DE LA MICROBIOLOGIE MEDICALE 2013;24:217-38. [PMID: 24489565 PMCID: PMC3905006 DOI: 10.1155/2013/781410] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
41
Werner CR, Egetemeyr DP, Lauer UM, Nadalin S, Königsrainer A, Malek NP, Berg CP. Telaprevir-based triple therapy in liver transplant patients with hepatitis C virus: a 12-week pilot study providing safety and efficacy data. Liver Transpl 2012;18:1464-70. [PMID: 22941516 DOI: 10.1002/lt.23542] [Citation(s) in RCA: 62] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/18/2012] [Accepted: 08/25/2012] [Indexed: 02/06/2023]
42
Mutimer D. Understanding the switchbacks: the impact of direct antivirals on the minimization of hepatitis C virus recurrence after transplantation. Liver Transpl 2012;18 Suppl 2:S47-51. [PMID: 22887985 DOI: 10.1002/lt.23533] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
43
Boceprevir: a protease inhibitor for the treatment of hepatitis C. Clin Ther 2012;34:2021-38. [PMID: 22975763 DOI: 10.1016/j.clinthera.2012.08.009] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2012] [Accepted: 08/17/2012] [Indexed: 02/07/2023]
44
Peginterferon-α-2b and ribavirin for hepatitis C recurrence postorthotopic liver transplantation. J Clin Gastroenterol 2012;46:700-8. [PMID: 22739223 DOI: 10.1097/mcg.0b013e31825833be] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]
45
Practical management of boceprevir and immunosuppressive therapy in liver transplant recipients with hepatitis C virus recurrence. Antimicrob Agents Chemother 2012;56:5728-34. [PMID: 22908172 DOI: 10.1128/aac.01151-12] [Citation(s) in RCA: 44] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]  Open
46
Akamatsu N, Sugawara Y. Liver transplantation and hepatitis C. Int J Hepatol 2012;2012:686135. [PMID: 22900194 PMCID: PMC3412106 DOI: 10.1155/2012/686135] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/09/2012] [Accepted: 05/21/2012] [Indexed: 02/07/2023]  Open
47
Lacek K, Vercauteren K, Grzyb K, Naddeo M, Verhoye L, Słowikowski MP, Fafi-Kremer S, Patel AH, Baumert TF, Folgori A, Leroux-Roels G, Cortese R, Meuleman P, Nicosia A. Novel human SR-BI antibodies prevent infection and dissemination of HCV in vitro and in humanized mice. J Hepatol 2012;57:17-23. [PMID: 22414763 DOI: 10.1016/j.jhep.2012.02.018] [Citation(s) in RCA: 66] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/16/2011] [Revised: 01/09/2012] [Accepted: 02/01/2012] [Indexed: 12/15/2022]
48
Perry CM. Telaprevir: a review of its use in the management of genotype 1 chronic hepatitis C. Drugs 2012;72:619-41. [PMID: 22439668 DOI: 10.2165/11208370-000000000-00000] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
49
Aghemo A, Bhoori S, De nicola S, Mazzaferro V, Colombo M. Failure of Intravenous Silibinin Monotherapy to Prevent Hepatitis C Genotype 2A Liver Graft Reinfection. HEPATITIS MONTHLY 2012;12:411-4. [PMID: 22879832 PMCID: PMC3412559 DOI: 10.5812/hepatmon.6135] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 05/07/2012] [Revised: 05/28/2012] [Accepted: 05/31/2012] [Indexed: 12/11/2022]
50
Vercauteren K, Leroux-Roels G, Meuleman P. Blocking HCV entry as potential antiviral therapy. Future Virol 2012. [DOI: 10.2217/fvl.12.47] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
PrevPage 1 of 2 12Next
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA